Press Releases

10.01.2020

Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene Therapy

09.28.2020

U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis

09.24.2020

Pfizer Declares Fourth-Quarter 2020 Dividend

09.23.2020

Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease

09.23.2020

FDA Accepts Supplemental New Drug Application for Pfizer’s XALKORI® (crizotinib) for the Treatment of Pediatric ALK-positive Anaplastic Large Cell Lymphoma

09.22.2020

Pfizer Invites Public to View and Listen to Webcast of October 27 Conference Call with Analysts

09.22.2020

Javelin Biotech Aims to Develop Industry-Leading “Organ-on-a-Chip” Predictive Pharmacokinetics Platform in Collaboration with Pfizer Inc.

09.18.2020

BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine

09.15.2020

Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas

09.14.2020

Pfizer Hosts Virtual Investor Day

09.12.2020

Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial

09.11.2020

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference